Summary of Talk
Camizestrant is a next-generation oral selective estrogen receptor degrader (ngSERD), discovered by AstraZeneca research teams in Cambridge and developed specifically to target ER+ breast cancer. In this presentation, we will highlight pivotal preclinical studies that identified camizestrant as a potent and highly selective degrader of the estrogen receptor (ER), confirming its profile as a complete antagonist with no residual agonist activity. Following its selection as a clinical candidate, we will review key early clinical trials conducted in patients with ER+ breast cancer, which paved the way for the positive Phase III SERENA-6 readout earlier this year.